Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report
Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown. Case: A 60-year-old female medical assistant, infected with COVID-19 in 10/2020, exp...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007125000048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199449242075136 |
|---|---|
| author | Stefanie Klampfleitner Andreas Fertl Ositha Prinz Martin Doerfler-Schalm Dieter Munker Markus O. Henke |
| author_facet | Stefanie Klampfleitner Andreas Fertl Ositha Prinz Martin Doerfler-Schalm Dieter Munker Markus O. Henke |
| author_sort | Stefanie Klampfleitner |
| collection | DOAJ |
| description | Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown. Case: A 60-year-old female medical assistant, infected with COVID-19 in 10/2020, experienced a complicated course of disease leading to tracheal stenosis. Various interventions, including stent placements and tracheal surgeries, were performed. Due to recurrent restenosis, the patient was treated with nintedanib, a tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis. The treatment spanned 306 days, during which the patient showed stability in pulmonary function. Nintedanib demonstrated a potential anti-inflammatory effect, reducing the frequency of interventions and prolonging stent-free intervals. The results suggest possible efficacy of nintedanib in managing scar-related granulation tissue, highlighting its potential in treating tracheal stenosis. Conclusion: This case shows a decreased need for interventions, and the longer duration of stent placement may suggest a potential role for nintedanib in diminishing hypertrophic scarring, possibly through an anti-inflammatory effect. Further exploration of this potential in additional clinical trials would be valuable. |
| format | Article |
| id | doaj-art-c82f6cd8a2d74e9d8a62c00e61f02648 |
| institution | Kabale University |
| issn | 2213-0071 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj-art-c82f6cd8a2d74e9d8a62c00e61f026482025-02-08T05:00:22ZengElsevierRespiratory Medicine Case Reports2213-00712025-01-0154102168Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case reportStefanie Klampfleitner0Andreas Fertl1Ositha Prinz2Martin Doerfler-Schalm3Dieter Munker4Markus O. Henke5Pulmonary Medicine, Hospital Martha-Maria, Munich, Germany; Emergency Center, Munich Clinic Schwabing, Munich, Germany; Corresponding author. Pulmonary Medicine, Hospital Martha-Maria, Munich, Germany.Pulmonary Medicine, Hospital Martha-Maria, Munich, GermanyPulmonary Medicine, Hospital Martha-Maria, Munich, GermanyPulmonary Medicine, Hospital Martha-Maria, Munich, GermanyPulmonary Medicine, Hospital Martha-Maria, Munich, GermanyPulmonary Medicine, Hospital Martha-Maria, Munich, Germany; Department of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps University of Marburg (UMR), Marburg, GermanyIntroduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown. Case: A 60-year-old female medical assistant, infected with COVID-19 in 10/2020, experienced a complicated course of disease leading to tracheal stenosis. Various interventions, including stent placements and tracheal surgeries, were performed. Due to recurrent restenosis, the patient was treated with nintedanib, a tyrosine kinase inhibitor used in idiopathic pulmonary fibrosis. The treatment spanned 306 days, during which the patient showed stability in pulmonary function. Nintedanib demonstrated a potential anti-inflammatory effect, reducing the frequency of interventions and prolonging stent-free intervals. The results suggest possible efficacy of nintedanib in managing scar-related granulation tissue, highlighting its potential in treating tracheal stenosis. Conclusion: This case shows a decreased need for interventions, and the longer duration of stent placement may suggest a potential role for nintedanib in diminishing hypertrophic scarring, possibly through an anti-inflammatory effect. Further exploration of this potential in additional clinical trials would be valuable.http://www.sciencedirect.com/science/article/pii/S2213007125000048 |
| spellingShingle | Stefanie Klampfleitner Andreas Fertl Ositha Prinz Martin Doerfler-Schalm Dieter Munker Markus O. Henke Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report Respiratory Medicine Case Reports |
| title | Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report |
| title_full | Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report |
| title_fullStr | Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report |
| title_full_unstemmed | Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report |
| title_short | Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report |
| title_sort | reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation a case report |
| url | http://www.sciencedirect.com/science/article/pii/S2213007125000048 |
| work_keys_str_mv | AT stefanieklampfleitner reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport AT andreasfertl reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport AT osithaprinz reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport AT martindoerflerschalm reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport AT dietermunker reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport AT markusohenke reducedtrachealstenosingeffectofnintedanibinapatientwithscarredposttraumatictrachealstenosisandairflowlimitationacasereport |